SPACEGEN -Human NTRK Genes Fusion Detection Kit (Mutiplex Fluorescence PCR)

Accuracy and Reliability:Use pre-load PCR tube to effectively avoid cross-contamination.

High Sensitivity: Sensitivity can reach as low as 100 copies in RNA

Comprehensive Coverage: Covers the 32 most common variants of the NTRK

Great versatility: Validated on the most common qPCR machines with stable results.

The NeuroTrophin Receptor Kinase (NTRK) family includes three proteins, TRKA, TRKB, and TRKC, encoded by the NTRK1, NTRK2, and NTRK3 genes, these proteins are normally expressed in neural tissues. Activation of TRK structures by NTRK gene fusions is considered as a pan-cancer oncogenic factor.

NTRK gene fusions are found in a variety of adult and pediatric solid tumors. In extremely rare tumor types such as infantile fibrosarcoma and secretory carcinoma, the frequency of NTRK fusion is more than 90%; in common cancers, the fusion frequency is between 0.1% and 2% .

Although in common cancers, NTRK fusion frequency is low ; however, in patients with fusion, the efficacy of NTRK inhibitors is very obvious. In 2019, 2020 and 2024, the FDA approved Larotrectinib, Entrectinib and Repotrectinib for the treatment of NTRK fusion-positive patients with advanced solid tumors without replacement therapy or progression. In 2023, the FDA expanded the indications of Entrectinib for use in pediatric patients.
Based on the above approval, the National Comprehensive Cancer Network has included NTRK inhibitors in several clinical diagnosis and treatment guidelines. The Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of non-small cell lung cancer (NSCLC) have also included NTRK inhibitors in the first-line treatment of stage IV NTRK fusion-positive NSCLC . The detection of NTRK fusions is also recommended in guidelines such as CSCO colorectal cancer.

Core Technology:PAP-ARMS®

Applicable Disease:Solid tumors

Instruments Validated:ABI7500, ABI7300, ABI StepOne Plus, LightCycler480, Bio-Rad CFX96, etc.

Sample Type:umor tissue,Pleural effusion &Ascites

Qualification:ISO13485 certificate, CAP，CE marking

 Pack Size:20 Tests/Kit

Before systemic treatment in patients with advanced or metastatic solid tumors, NTRK gene fusion detection is performed for molecular typing to help guide treatments.